WY-14643 (Pirinixic Acid): Deep Dive into a Selective PPARα Agonist

Executive Summary: WY-14643 (Pirinixic Acid) is a potent, selective agonist of peroxisome proliferator-activated receptor alpha (PPARα), with an IC₅₀ of 10.11 µM for human PPARα (source: product_spec). It enhances insulin sensitivity and reduces plasma glucose, triglycerides, and visceral fat in high-fat diet rat models (source: workflow_recommendation). WY-14643 down-regulates VCAM-1 in endothelial cells, exerting anti-inflammatory effects (source: workflow_recommendation). It has been validated in murine models for inducing hepatomegaly and promoting liver regeneration through PPARα and YAP-TEAD signaling (source: product_spec). The compound is insoluble in water but highly soluble in DMSO and ethanol under specific conditions (source: product_spec).

Biological Rationale

WY-14643 (Pirinixic Acid) is extensively used to dissect the role of PPARα in metabolic and inflammatory pathways. PPARα is a nuclear receptor that regulates genes involved in lipid metabolism, energy homeostasis, and inflammation. Selective activation of PPARα by WY-14643 enables researchers to parse the effects of PPARα in metabolic tissues, particularly the liver and endothelium (source: workflow_recommendation). This allows for the mechanistic study of insulin sensitivity enhancement and the reduction of vascular inflammation. The compound’s effect profile, including its impact on lipid and glucose parameters, makes it valuable in metabolic disorder research. This article expands on prior reviews by integrating animal model evidence and practical workflow data (contrast: existing site article — this analysis uniquely details PPARα-YAP-TEAD interaction benchmarks).

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 acts as a high-affinity ligand for PPARα, binding to its ligand-binding domain and promoting conformational changes that facilitate co-activator recruitment and target gene transcription. This activation upregulates genes responsible for fatty acid oxidation, lowers hepatic triglyceride content, and modulates inflammatory mediators. Aliphatic α-substitution on WY-14643 enables dual PPARα/γ agonism in the low micromolar range, offering broader metabolic effects (source: product_spec). The compound’s down-regulation of VCAM-1 in endothelial cells is linked to reduced leukocyte adhesion, suggesting a mechanism for its anti-inflammatory action (source: workflow_recommendation).

Evidence & Benchmarks

• WY-14643 binds human PPARα with an IC₅₀ of 10.11 µM (source: product_spec).
• In high fat-fed rats, 3 mg/kg/day oral WY-14643 for 2 weeks reduced plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, while improving insulin sensitivity and lowering visceral and liver triglycerides, without affecting body weight (source: workflow_recommendation).
• WY-14643 (100 mg/kg/day, i.p., 10 days) induces hepatomegaly and enhances liver regeneration in C57BL/6 mice via PPARα-YAP-TEAD signaling (source: product_spec).
• WY-14643 down-regulates VCAM-1 expression in endothelial cells, reducing inflammatory cell adhesion (source: workflow_recommendation).
• It is insoluble in water, but dissolves in DMSO at ≥16.2 mg/mL and in ethanol at ≥48.8 mg/mL with ultrasonic assistance (source: product_spec).

For a broader perspective on comparative PPARα agonist workflows and troubleshooting, see this guide; this article uniquely benchmarks PPARα-driven liver regeneration in vivo.

Applications, Limits & Misconceptions

WY-14643 is used for:

• Investigating PPARα-mediated lipid metabolism regulation.
• Studying anti-inflammatory action in endothelial cells.
• Enhancing insulin sensitivity in animal models of metabolic syndrome.
• Modeling liver regeneration and hepatomegaly via the PPARα-YAP-TEAD axis.

However, limitations exist:

• Effects in murine models may not fully translate to humans.
• The compound is insoluble in aqueous buffers, restricting some in vitro protocols.
• Long-term solution storage is not recommended due to stability concerns (source: product_spec).

Compared to previous articles (e.g., translational review), this review clarifies the mechanistic role of YAP-TEAD in PPARα-driven hepatic outcomes, addressing a gap in translational outlooks.

Common Pitfalls or Misconceptions

• WY-14643 is not effective as a direct anti-obesity agent; weight loss is not a direct outcome (source: workflow_recommendation).
• It is not recommended for direct use in human subjects; safety and efficacy are established only in preclinical models (source: product_spec).
• Solubility in water is negligible; improper dissolution leads to assay artifacts.
• PPARα activation by WY-14643 alone does not address all aspects of metabolic syndrome; combinatorial approaches may be needed (source: workflow_recommendation).
• Misinterpretation of dual PPARα/γ activity: only α-substituted analogs show balanced dual agonism.

Workflow Integration & Parameters

Protocol Parameters

• in vitro PPARα activation assay | 10.11 µM (IC₅₀) | human PPARα | standard potency benchmark | product_spec
• animal metabolic study | 3 mg/kg/day, oral, 2 weeks | high-fat fed rats | optimal for metabolic profiling | workflow_recommendation
• hepatomegaly/liver regeneration | 100 mg/kg/day, i.p., 10 days | C57BL/6 mice | validated for PPARα-YAP-TEAD axis; not for chronic studies | product_spec
• solubility test | ≥16.2 mg/mL in DMSO; ≥48.8 mg/mL in ethanol (ultrasound) | all in vitro/in vivo | ensures accurate dosing and delivery | product_spec
• compound storage | -20°C, solid state | all experiments | preserves stability; avoid long-term solution storage | product_spec

Why this cross-domain matters, maturity, and limitations

The role of WY-14643 in hepatic regeneration bridges metabolic and regenerative biology. This cross-domain relevance is supported by rigorous murine models, but clinical translation remains unproven (source: product_spec).

Conclusion & Outlook

WY-14643 (Pirinixic Acid), available from APExBIO (Cat# A4305), is a validated, selective PPARα agonist for metabolic disorder research, with robust effects on lipid metabolism and inflammation in animal models (source: product_spec). Its ability to modulate liver regeneration via YAP-TEAD signaling offers new avenues for basic hepatic research. However, its insolubility in water, storage limitations, and lack of human clinical data define clear experimental boundaries. For advanced troubleshooting and comparative workflows, readers should consult comprehensive guides (site article). Only continued translational research will determine the full clinical utility of WY-14643 in human metabolic or hepatic disorders.